Improving pediatric multiple sclerosis interventional phase III study design: a meta-analysis.

"Conflict of interest statement: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: J.S.G. over the past year received grant/contract research support from the National Multiple Sclerosis Society, Biogen, and Octave Biosciences; she serves on a steering committee for a trial supported by Novartis; she has received honoraria for a non-promotional, educational activity for Sanofi-Genzyme; she has received speaker fees from Alexion and Bristol Myers Squibb (BMS) and served on an advisory board for Genentech. M.T. and J.L. are the employees of Novartis Pharma AG. A.S. is an employee of Novartis Healthcare Pvt. Ltd. A.G. was an employee of Novartis at the time of article development. M.R.L., H.S., and D.A.H. are the employees of Novartis Pharma AG. T.F. reports personnel fees for consultancies (including data monitoring committees and steering committees) from Bayer, Biosense Webster, Boehringer Ingelheim, Coherex Medical, CSL Behring, Daiichi Sankyo, Fresenius Kabi, Galapagos, Janssen, LivaNova, Novartis, Penumbra, Roche, and Vifor. J.G. reports consultant fees for research, lectures, and advisory boards from Bayer, Biogen, Novartis, Sanofi, and Teva; she also received financial support for a research project from Novartis."

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The study sponsor (Novartis Pharma AG, Basel, Switzerland) participated in the design and conduct of the study, data collection, data management, data analysis, and data interpretation; in the preparation, review, and approval of the article and writing of the report; and in the decision to submit the paper for publication. All authors had full access to all study data and had final responsibility for the decision to submit for publication. The article processing charges for this publication were funded by Novartis Pharma AG, Basel, Switzerland."